Please login to the form below

Not currently logged in
Email:
Password:

eliglustat

This page shows the latest eliglustat news and features for those working in and with pharma, biotech and healthcare.

R&D productivity takes off

R&D productivity takes off

Among these, notable examples include PTC Therapeutics' Translarna (ataluren) - the first medicine approved for the treatment of Duchenne muscular dystrophy (DMD) - and Sanofi/Genzyme's Cerdelga (eliglustat) for Gaucher disease, a

Latest news

  • Genzyme's oral Gaucher drug cleared in Europe Genzyme's oral Gaucher drug cleared in Europe

    Cerdelga (eliglustat) has been cleared by the European Commission (EC) for adults living with Gaucher disease type 1, according to Genzyme's parent Sanofi, which says the drug "will be available

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    advisers. The Committee for Medicinal Products for Human Use (CHMP) backed Genzyme's Cerdelga (eliglustat) and Boehringer Ingelheim's Ofev (nintedanib) in its latest round of opinions - which are usually followed

  • Sanofi plans 18 new product launches by 2020 Sanofi plans 18 new product launches by 2020

    The remainder of its growth portfolio are Cerdelga (eliglustat) for Gaucher disease - the only approved oral, first-line therapy for the rare genetic disease, Lemtrada (alemtuzumab) for multiple sclerosis and sarilumab,

  • FDA gives green light to Genzyme’s oral Gaucher drug FDA gives green light to Genzyme’s oral Gaucher drug

    Genzyme has said it plans to launch Cerdelga (eliglustat), a drug in the glucosylceramide class, within the next month, giving it an oral therapy to suit alongside its widely-used enzyme ... Cerezyme is already the biggest-selling drug for Gaucher

  • Genzyme on track for eliglustat filing in 2013 Genzyme on track for eliglustat filing in 2013

    The new data puts eliglustat on track for filing this year with approval potentially coming in 2014. ... Genzyme maintains that eliglustat works in a slightly different way which means it is considerably more potent than miglustat.

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics